Rallybio Corporaton (RLYB) Stock Price, Quote & News

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-tar...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 859 3820

Website: www.rallybio.com

Address:

234 Church Street, Suite 1020, New Haven, United States

Dardpro Jun. 25 at 12:12 AM

$RLYB anyone still alive here? Almost sold at .30, now holding 😂

1 · Reply

ShemimiTv Jun. 16 at 5:15 PM

Thoughts on these tickers? Watching for breakout setups: $SNSE $ORKT $WWR $RLYB

0 · Reply

HjalmarTheGreat Jun. 16 at 4:42 PM

$RLYB Still hanging around here. I will always be here until I get what I want.

1 · Reply

Dardpro Jun. 12 at 2:56 PM

$RLYB We might still need to wait until August to see some movement. A lottery, for sure. GL

0 · Reply

WEAREBACK Jun. 12 at 2:42 PM

$RLYB https://investors.rallybio.com/news-releases/news-release-details/rallybio-initiates-dosing-rlyb116-phase-1-confirmatory

0 · Reply

TWITLIEDETECTOR Jun. 8 at 7:01 AM

$RLYB Stock appears to be turning bullish. Can anyone please share why it crashed in early April?

1 · Reply

Dardpro Jun. 6 at 3:18 PM

$RLYB we getting into some interesting volatility/volume.

0 · Reply

AHA_OHO Jun. 4 at 4:29 PM

$RLYB any news?

1 · Reply

Stockttwits619 Jun. 4 at 4:28 PM

$GNLN $HCTI scalping $CLRB $RLYB $APM

0 · Reply

Dardpro Jun. 4 at 3:54 PM

$RLYB dang my orders got filled, keeping the rest. GL bulls

0 · Reply

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

May 8, 2025, 8:00 AM EDT - 7 weeks ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 29, 2025, 8:00 AM EDT - 2 months ago

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Apr 8, 2025, 1:01 PM EDT - 2 months ago

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Apr 8, 2025, 8:00 AM EDT - 2 months ago

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Mar 13, 2025, 8:00 AM EDT - 3 months ago

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Feb 25, 2025, 8:00 AM EST - 4 months ago

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 11, 2025, 8:00 AM EST - 4 months ago

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Jan 10, 2025, 8:00 AM EST - 6 months ago

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Dec 10, 2024, 8:00 AM EST - 7 months ago

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Dec 2, 2024, 8:00 AM EST - 7 months ago

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Nov 27, 2024, 8:00 AM EST - 7 months ago

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Nov 26, 2024, 8:00 AM EST - 7 months ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Nov 25, 2024, 8:00 AM EST - 7 months ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Nov 21, 2024, 8:00 AM EST - 7 months ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Nov 7, 2024, 8:00 AM EST - 8 months ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 29, 2024, 8:00 AM EDT - 8 months ago

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Sep 30, 2024, 8:00 AM EDT - 9 months ago

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Sep 23, 2024, 8:00 AM EDT - 9 months ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Sep 10, 2024, 8:00 AM EDT - 10 months ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Sep 9, 2024, 5:15 PM EDT - 10 months ago

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Aug 29, 2024, 8:00 AM EDT - 10 months ago

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Aug 27, 2024, 8:00 AM EDT - 10 months ago

National Vision Releases 2023 Sustainability Report

ACNT

Aug 27, 2024, 8:00 AM EDT - 10 months ago

Rallybio to Present at Upcoming Investor Conferences

Aug 8, 2024, 8:00 AM EDT - 11 months ago

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

May 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Apr 17, 2024, 4:01 PM EDT - 1 year ago

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Apr 10, 2024, 4:01 PM EDT - 1 year ago

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Apr 1, 2024, 10:05 AM EDT - 1 year ago

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 8:00 AM EST - 1 year ago

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Jan 4, 2024, 8:00 AM EST - 1 year ago

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Dec 20, 2023, 8:00 AM EST - 1 year ago

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Dec 9, 2023, 12:00 PM EST - 1 year ago

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Nov 28, 2023, 7:00 AM EST - 1 year ago

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Nov 9, 2023, 8:00 AM EST - 1 year ago

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 8, 2023, 8:00 AM EST - 1 year ago

Rallybio to Present at Upcoming Investor Conferences in November

Nov 2, 2023, 9:15 AM EDT - 1 year ago

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

Sep 15, 2023, 5:15 PM EDT - 1 year ago

Rallybio: Gearing Up To Be An Opportunity

Sep 3, 2023, 12:00 PM EDT - 1 year ago

Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Aug 31, 2023, 8:00 AM EDT - 1 year ago

Rallybio to Present at Upcoming Investor Conferences in September

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference

Jul 11, 2023, 8:00 AM EDT - 2 years ago

Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

Dardpro Jun. 25 at 12:12 AM

$RLYB anyone still alive here? Almost sold at .30, now holding 😂

1 · Reply

ShemimiTv Jun. 16 at 5:15 PM

Thoughts on these tickers? Watching for breakout setups: $SNSE $ORKT $WWR $RLYB

0 · Reply

HjalmarTheGreat Jun. 16 at 4:42 PM

$RLYB Still hanging around here. I will always be here until I get what I want.

1 · Reply

Dardpro Jun. 12 at 2:56 PM

$RLYB We might still need to wait until August to see some movement. A lottery, for sure. GL

0 · Reply

WEAREBACK Jun. 12 at 2:42 PM

$RLYB https://investors.rallybio.com/news-releases/news-release-details/rallybio-initiates-dosing-rlyb116-phase-1-confirmatory

0 · Reply

TWITLIEDETECTOR Jun. 8 at 7:01 AM

$RLYB Stock appears to be turning bullish. Can anyone please share why it crashed in early April?

1 · Reply

Dardpro Jun. 6 at 3:18 PM

$RLYB we getting into some interesting volatility/volume.

0 · Reply

AHA_OHO Jun. 4 at 4:29 PM

$RLYB any news?

1 · Reply

Stockttwits619 Jun. 4 at 4:28 PM

$GNLN $HCTI scalping $CLRB $RLYB $APM

0 · Reply

Dardpro Jun. 4 at 3:54 PM

$RLYB dang my orders got filled, keeping the rest. GL bulls

0 · Reply

Dardpro Jun. 4 at 3:36 PM

$RLYB I like it...

0 · Reply

Dardpro Jun. 3 at 2:29 PM

$RLYB WHAT IN THE FCKKK IS HAPPENING.!

2 · Reply

HjalmarTheGreat May. 23 at 2:00 PM

$RLYB Talking to myself.

1 · Reply

HjalmarTheGreat May. 21 at 1:52 PM

$RLYB Short attack this morning, 250,000 shares. Attempted to buy but Pac-man beat me to it.

0 · Reply

HjalmarTheGreat May. 20 at 2:00 PM

$RLYB This company has $54.5 million dollars on hand; enough to carry them into 2027. We will see clinical results for 116 later this year. Nice preclinical pipeline. Only been trading below a dollar since January, so plenty of time to regain compliance. Round two for me, cautiously trading after after my shirt was ripped away by 212.

1 · Reply

HjalmarTheGreat May. 19 at 4:26 PM

$RLYB Still buying here. This has no business down here even with the discontinuation of 212. Lost bigly there. It was a bad day. This is a nice pipeline even without it.

0 · Reply

Dardpro May. 16 at 4:57 PM

$INO anyone on this baby doll, also check out $RLYB ,looks like it wants to squeeeze soon. GL

0 · Reply

Dardpro May. 15 at 1:06 PM

$RLYB will today be the day?

0 · Reply

TheLearnerEarner May. 12 at 12:40 PM

$RLYB According to Fintel website, RLYB is now F-Score 3/9 🏦

1 · Reply

TheLearnerEarner May. 9 at 1:40 PM

$RLYB ✅ Energy - mid cap - 0.99x relative volume F-Score: 2/9 🏦 Analysts: 5x buy rating 👨‍🔬 Intrinsic Value Potential: Superb 💎 RSI: 39.50 (oversold bullish) 📊🐂 Analysts Price Target: $2.03 - $7.80 (137% - 811% above Price) 🌟 Range (12m) $0.22 - $2.00 💰 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/PLUG/plug-power-closes-525-million-secured-credit-facility-with-yorkville-nixkmtygl7t3.html

2 · Reply

justiceforb_85 May. 9 at 4:04 AM

$RLYB unfortunately with failure of RLYB212 in FNAIT this company is facing stiff competition for its revised pipeline.

1 · Reply

TheLearnerEarner May. 8 at 8:09 PM

$RLYB ✅ Healthcare - micro cap - 0.68x relative volume F-Score: 2/9 🏦 Analysts: 1x buy rating 👨‍🔬 Intrinsic Value Potential: Excellent 💎 RSI: 35.88 (oversold bullish) 📊🐂 Analysts Price Target: $1.00 - $7.00 (232% - 2227% above Price) 🌟 Range (12m) $0.22 - $2.00 💰 NEWSDESK (last recent article) 📰 https://uk.finance.yahoo.com/news/rallybio-reports-first-quarter-2025-120000377.html

0 · Reply

Market Cap	15.09M
Revenue (ttm)	640,000.00
Net Income (ttm)	-57.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9,028.13%
Debt to Equity Ratio	0.00

Volume	129,700
Avg Vol	181,226
Day's Range	N/A - N/A
Shares Out	41.61M
Stochastic %K	41%
Beta	-1.24
Analysts	Sell
Price Target	$1.00